Login to Your Account



Clinic Roundup


Wednesday, January 5, 2011
Isis Pharmaceuticals Inc., of Carlsbad, Calif., started two Phase II studies of ISIS-EIF4ERx, a drug targeting eukaryotic initiation of factor-4E.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription